



# Roundhill GLP-1 & Weight Loss ETF



OZEM (Principal U.S. Listing Exchange: NASDAQ)

Annual Shareholder Report | December 31, 2024

This annual shareholder report contains important information about the Roundhill GLP-1 & Weight Loss ETF for the period of January 1, 2024, to December 31, 2024, as well as certain changes to the Fund. You can find additional information about the Fund at <https://www.roundhillinvestments.com/etf/>. You can also request this information by contacting us at 800-617-0004.

## WHAT WERE THE FUND COSTS FOR THE PAST YEAR? (based on a hypothetical \$10,000 investment)\*

Fund Name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
Roundhill GLP-1 & Weight Loss ETF	\$36	0.59%

\* Expense ratio is annualized. Amount shown reflects the expenses of the Fund for the current fiscal period. Expenses would be higher if the Fund had been in operations for a full year.

## HOW DID THE FUND PERFORM LAST YEAR AND WHAT AFFECTED ITS PERFORMANCE?

The Roundhill GLP-1 & Weight Loss ETF (the “Fund”) pursues its investment objective by seeking to provide exposure to companies involved in the development of pharmaceutical drugs and/or supplements that can be utilized to help individuals lose weight, maintain an ideal weight, and/or maintain body composition during weight loss (“GLP-1 & Weight Loss Drugs”). The Fund will focus its investments in the securities of companies that are the acknowledged leaders in the development of GLP-1 & Weight Loss Drugs, which it defines as those companies that have GLP-1 & Weight Loss Drugs currently undergoing Phase I, Phase II, and/or Phase III of U.S. Food & Drug Administration (“FDA”) clinical trials and in securities of companies with GLP-1 & Weight Loss Drugs that have been approved by the FDA (“GLP-1 & Weight Loss Companies”). For non-U.S. companies that are not subject to oversight by the FDA, the Fund may classify such company as a GLP-1 & Weight Loss Company if that company’s GLP-1 & Weight Loss Drug is currently undergoing clinical trials subject to regulatory oversight by that company’s applicable food and drug regulator or if that company’s GLP-1 & Weight Loss Drug has been approved by the company’s applicable food and drug regulator.

### PERFORMANCE


The following information pertains to the fiscal period of May 20, 2024 through December 31, 2024 (the “current fiscal period”). Please note, the Fund was listed during the reporting period, and as such the Fund’s data reflects from inception to the end of the current fiscal period.

The Fund had negative performance during the current fiscal period. The market price and NAV for the Fund decreased by 3.31% and 3.11%, respectively. The Solactive GBS Global Markets All Cap USD Index TR returned 6.31% over the same period.

## HOW DID THE FUND PERFORM SINCE INCEPTION?\*

The \$10,000 chart reflects a hypothetical \$10,000 investment in the class of shares noted and assumes the maximum sales charge. The chart uses total return NAV performance and assumes reinvestment of dividends and capital gains. Fund expenses, including 12b-1 fees, management fees and other expenses were deducted.

## CUMULATIVE PERFORMANCE (Initial Investment of \$10,000)



## ANNUAL AVERAGE TOTAL RETURN (%)

Since Inception  
(05/20/2024)

Roundhill GLP-1 & Weight Loss ETF NAV	-3.11
Solactive GBS Global Markets All Cap USD Index TR	6.31

Visit <https://www.roundhillinvestments.com/etf/> for more recent performance information.

\* The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on Fund distributions or redemption of Fund shares.

## KEY FUND STATISTICS (as of December 31, 2024)

Net Assets	\$39,790,254
Number of Holdings	29
Net Advisory Fee	\$142,005
Portfolio Turnover	37%
30-Day SEC Yield	0.76%

Visit <https://www.roundhillinvestments.com/etf/> for more recent performance information.

## WHAT DID THE FUND INVEST IN? (as of December 31, 2024)

Top 10 Issuers (%)	Top Sectors (%)
Eli Lilly & Co. 16.1%	Consumer, Non-cyclical 99.9%
Novo Nordisk AS 15.2%	Cash & Other 0.1%
Roche Holding AG 5.3%	
Zealand Pharma AS 4.7%	
AstraZeneca PLC 4.4%	
Chugai Pharmaceutical Co. Ltd. 4.4%	
Amgen, Inc. 3.9%	
Innovent Biologics, Inc. 3.8%	
Pfizer, Inc. 3.8%	
Viking Therapeutics, Inc. 3.5%	

For additional information about the Fund; including its prospectus, financial information, holdings and proxy information, scan the QR code or visit <https://www.roundhillinvestments.com/etf/>.

## HOUSEHOLDING

To reduce Fund expenses, only one copy of most shareholder documents may be mailed to shareholders with multiple accounts at the same address (Householding). If you would prefer that your Roundhill Financial LLC documents not be householded, please contact Roundhill Financial LLC at 800-617-0004, or contact your financial intermediary. Your instructions will typically be effective within 30 days of receipt by Roundhill Financial LLC or your financial intermediary.